Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib: A Population-Based Retrospective Cohort Study.

ABSTRACT:

Background

Osimertinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat patients with epidermal growth factor receptor-mutant non-small-cell lung cancer. Although osimertinib has been linked to heart failure (HF), detailed risk estimates remain unclear.

Objectives

The aim of this study was to examine the association between osimertinib use and HF hospitalization.

Methods

In this retrospective cohort study using a large-scale Japanese claims database, patients diagnosed with lung cancer between April 2008 and December 2021 who received cancer therapy were identified. Patients were categorized into osimertinib and control groups according to treatment received. The incidence of HF hospitalization during the treatment period was compa

SUBMITTER: Tatebe Y 

PROVIDER: S-EPMC12790068 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature